Strong sales of its obesity injections pushed Lilly past profit expectations, and the drugmaker raised its full-year outlook, Reuters reports.
Recap by typeshit. Full story at Reuters on MSN.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
On his podcast, Khan cites studies suggesting hunger hormones rebound within four weeks and about 60% of lost weight comes back within a year.
Pharmacies need FDA-registered suppliers, contaminant testing and MedWatch reporting. A UVA doctor told AJMC gray-market vials often hold 5% to 75% of the labeled dose.
Loading…